PACIRA BIOSCIENCES INC (PCRX) Fundamental Analysis & Valuation

NASDAQ:PCRX • US6951271005

Current stock price

24.88 USD
+0.24 (+0.97%)
At close:
24.88 USD
0 (0%)
Pre-Market:

This PCRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. PCRX Profitability Analysis

1.1 Basic Checks

  • PCRX had positive earnings in the past year.
  • In the past year PCRX had a positive cash flow from operations.
  • Of the past 5 years PCRX 4 years were profitable.
  • In the past 5 years PCRX always reported a positive cash flow from operatings.
PCRX Yearly Net Income VS EBIT VS OCF VS FCFPCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

1.2 Ratios

  • PCRX has a better Return On Assets (0.56%) than 79.58% of its industry peers.
  • PCRX has a Return On Equity of 1.01%. This is amongst the best in the industry. PCRX outperforms 81.15% of its industry peers.
  • The Return On Invested Capital of PCRX (2.67%) is better than 80.63% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for PCRX is significantly below the industry average of 13.11%.
Industry RankSector Rank
ROA 0.56%
ROE 1.01%
ROIC 2.67%
ROA(3y)-1.06%
ROA(5y)-0.04%
ROE(3y)-2.32%
ROE(5y)0.17%
ROIC(3y)4.67%
ROIC(5y)4.88%
PCRX Yearly ROA, ROE, ROICPCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

1.3 Margins

  • Looking at the Profit Margin, with a value of 0.97%, PCRX is in the better half of the industry, outperforming 79.58% of the companies in the same industry.
  • PCRX's Profit Margin has declined in the last couple of years.
  • PCRX has a Operating Margin of 5.33%. This is in the better half of the industry: PCRX outperforms 79.58% of its industry peers.
  • PCRX's Operating Margin has declined in the last couple of years.
  • PCRX's Gross Margin of 79.39% is amongst the best of the industry. PCRX outperforms 84.82% of its industry peers.
  • PCRX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 5.33%
PM (TTM) 0.97%
GM 79.39%
OM growth 3Y-20.59%
OM growth 5Y-17.68%
PM growth 3Y-25.95%
PM growth 5Y-50.88%
GM growth 3Y4.23%
GM growth 5Y1.78%
PCRX Yearly Profit, Operating, Gross MarginsPCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. PCRX Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PCRX is destroying value.
  • The number of shares outstanding for PCRX has been reduced compared to 1 year ago.
  • PCRX has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, PCRX has an improved debt to assets ratio.
PCRX Yearly Shares OutstandingPCRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
PCRX Yearly Total Debt VS Total AssetsPCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • PCRX has an Altman-Z score of 1.92. This is not the best score and indicates that PCRX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • PCRX has a Altman-Z score (1.92) which is comparable to the rest of the industry.
  • PCRX has a debt to FCF ratio of 2.72. This is a good value and a sign of high solvency as PCRX would need 2.72 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 2.72, PCRX belongs to the top of the industry, outperforming 91.62% of the companies in the same industry.
  • A Debt/Equity ratio of 0.54 indicates that PCRX is somewhat dependend on debt financing.
  • PCRX has a worse Debt to Equity ratio (0.54) than 66.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF 2.72
Altman-Z 1.92
ROIC/WACC0.31
WACC8.57%
PCRX Yearly LT Debt VS Equity VS FCFPCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 4.54 indicates that PCRX has no problem at all paying its short term obligations.
  • PCRX's Current ratio of 4.54 is fine compared to the rest of the industry. PCRX outperforms 61.78% of its industry peers.
  • A Quick Ratio of 3.28 indicates that PCRX has no problem at all paying its short term obligations.
  • PCRX has a Quick ratio (3.28) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.54
Quick Ratio 3.28
PCRX Yearly Current Assets VS Current LiabilitesPCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. PCRX Growth Analysis

3.1 Past

  • The earnings per share for PCRX have decreased strongly by -18.07% in the last year.
  • Measured over the past 5 years, PCRX shows a small growth in Earnings Per Share. The EPS has been growing by 3.64% on average per year.
  • The Revenue for PCRX has decreased by -16.32% in the past year. This is quite bad
  • Measured over the past years, PCRX shows a quite strong growth in Revenue. The Revenue has been growing by 11.08% on average per year.
EPS 1Y (TTM)-18.07%
EPS 3Y0.51%
EPS 5Y3.64%
EPS Q2Q%-37.36%
Revenue 1Y (TTM)-16.32%
Revenue growth 3Y2.9%
Revenue growth 5Y11.08%
Sales Q2Q%5.14%

3.2 Future

  • PCRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.64% yearly.
  • PCRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.42% yearly.
EPS Next Y2.7%
EPS Next 2Y16.4%
EPS Next 3Y20.27%
EPS Next 5Y10.64%
Revenue Next Year4.19%
Revenue Next 2Y6.34%
Revenue Next 3Y8.72%
Revenue Next 5Y5.42%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
PCRX Yearly Revenue VS EstimatesPCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
PCRX Yearly EPS VS EstimatesPCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. PCRX Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 9.46, the valuation of PCRX can be described as reasonable.
  • 93.19% of the companies in the same industry are more expensive than PCRX, based on the Price/Earnings ratio.
  • PCRX is valuated cheaply when we compare the Price/Earnings ratio to 27.50, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 9.21, which indicates a very decent valuation of PCRX.
  • Based on the Price/Forward Earnings ratio, PCRX is valued cheaply inside the industry as 89.53% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 22.62. PCRX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 9.46
Fwd PE 9.21
PCRX Price Earnings VS Forward Price EarningsPCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaper than 91.10% of the companies in the same industry.
  • 95.81% of the companies in the same industry are more expensive than PCRX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 7.37
EV/EBITDA 8.18
PCRX Per share dataPCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of PCRX may justify a higher PE ratio.
  • A more expensive valuation may be justified as PCRX's earnings are expected to grow with 20.27% in the coming years.
PEG (NY)3.51
PEG (5Y)2.6
EPS Next 2Y16.4%
EPS Next 3Y20.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PCRX Dividend Analysis

5.1 Amount

  • No dividends for PCRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PCRX Fundamentals: All Metrics, Ratios and Statistics

PACIRA BIOSCIENCES INC

NASDAQ:PCRX (4/22/2026, 8:00:00 PM)

Premarket: 24.88 0 (0%)

24.88

+0.24 (+0.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)04-30
Inst Owners119.39%
Inst Owner Change0.07%
Ins Owners2.16%
Ins Owner Change16.51%
Market Cap1.01B
Revenue(TTM)726.41M
Net Income(TTM)7.03M
Analysts76.92
Price Target29.29 (17.73%)
Short Float %20.59%
Short Ratio10.45
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.46%
Min EPS beat(2)-38.21%
Max EPS beat(2)5.28%
EPS beat(4)3
Avg EPS beat(4)-7.2%
Min EPS beat(4)-38.21%
Max EPS beat(4)5.28%
EPS beat(8)6
Avg EPS beat(8)1.27%
EPS beat(12)7
Avg EPS beat(12)-1.33%
EPS beat(16)7
Avg EPS beat(16)-6.57%
Revenue beat(2)0
Avg Revenue beat(2)-3.64%
Min Revenue beat(2)-3.7%
Max Revenue beat(2)-3.59%
Revenue beat(4)0
Avg Revenue beat(4)-4.05%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-2.99%
Revenue beat(8)1
Avg Revenue beat(8)-2.33%
Revenue beat(12)1
Avg Revenue beat(12)-2.76%
Revenue beat(16)1
Avg Revenue beat(16)-2.75%
PT rev (1m)-3.37%
PT rev (3m)-3.37%
EPS NQ rev (1m)-1.58%
EPS NQ rev (3m)-21.29%
EPS NY rev (1m)-11.96%
EPS NY rev (3m)-22.79%
Revenue NQ rev (1m)-1.83%
Revenue NQ rev (3m)-6.05%
Revenue NY rev (1m)-0.29%
Revenue NY rev (3m)-3.76%
Valuation
Industry RankSector Rank
PE 9.46
Fwd PE 9.21
P/S 1.39
P/FCF 7.37
P/OCF 6.63
P/B 1.45
P/tB 3.31
EV/EBITDA 8.18
EPS(TTM)2.63
EY10.57%
EPS(NY)2.7
Fwd EY10.86%
FCF(TTM)3.38
FCFY13.57%
OCF(TTM)3.75
OCFY15.09%
SpS17.94
BVpS17.12
TBVpS7.53
PEG (NY)3.51
PEG (5Y)2.6
Graham Number31.8271 (27.92%)
Profitability
Industry RankSector Rank
ROA 0.56%
ROE 1.01%
ROCE 3.38%
ROIC 2.67%
ROICexc 3.38%
ROICexgc 5.91%
OM 5.33%
PM (TTM) 0.97%
GM 79.39%
FCFM 18.81%
ROA(3y)-1.06%
ROA(5y)-0.04%
ROE(3y)-2.32%
ROE(5y)0.17%
ROIC(3y)4.67%
ROIC(5y)4.88%
ROICexc(3y)6.66%
ROICexc(5y)7.23%
ROICexgc(3y)14.37%
ROICexgc(5y)26.99%
ROCE(3y)5.91%
ROCE(5y)6.18%
ROICexgc growth 3Y-17.07%
ROICexgc growth 5Y-17.82%
ROICexc growth 3Y-9.16%
ROICexc growth 5Y-18.82%
OM growth 3Y-20.59%
OM growth 5Y-17.68%
PM growth 3Y-25.95%
PM growth 5Y-50.88%
GM growth 3Y4.23%
GM growth 5Y1.78%
F-Score8
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF 2.72
Debt/EBITDA 2.87
Cap/Depr 16.85%
Cap/Sales 2.11%
Interest Coverage 2.54
Cash Conversion 117.14%
Profit Quality 1942.86%
Current Ratio 4.54
Quick Ratio 3.28
Altman-Z 1.92
F-Score8
WACC8.57%
ROIC/WACC0.31
Cap/Depr(3y)16.8%
Cap/Depr(5y)48.87%
Cap/Sales(3y)1.96%
Cap/Sales(5y)3.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.07%
EPS 3Y0.51%
EPS 5Y3.64%
EPS Q2Q%-37.36%
EPS Next Y2.7%
EPS Next 2Y16.4%
EPS Next 3Y20.27%
EPS Next 5Y10.64%
Revenue 1Y (TTM)-16.32%
Revenue growth 3Y2.9%
Revenue growth 5Y11.08%
Sales Q2Q%5.14%
Revenue Next Year4.19%
Revenue Next 2Y6.34%
Revenue Next 3Y8.72%
Revenue Next 5Y5.42%
EBIT growth 1Y-65.3%
EBIT growth 3Y-18.29%
EBIT growth 5Y-8.56%
EBIT Next Year0.28%
EBIT Next 3Y34.34%
EBIT Next 5Y7.61%
FCF growth 1Y-23.55%
FCF growth 3Y5.86%
FCF growth 5Y28.37%
OCF growth 1Y-19.75%
OCF growth 3Y1.51%
OCF growth 5Y14.57%

PACIRA BIOSCIENCES INC / PCRX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?

ChartMill assigns a fundamental rating of 6 / 10 to PCRX.


Can you provide the valuation status for PACIRA BIOSCIENCES INC?

ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.


Can you provide the profitability details for PACIRA BIOSCIENCES INC?

PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 6 / 10.


What is the financial health of PACIRA BIOSCIENCES INC (PCRX) stock?

The financial health rating of PACIRA BIOSCIENCES INC (PCRX) is 7 / 10.